The purpose of this study is to test a new COVID-19 vaccine to determine if it is safe and works to stimulate an immune response that may prevent COVID-19 disease.
COVID-19 is a new, contagious disease that has quickly infected many people all over the world. The symptoms usually include fever, cough, and shortness of breath lasting several days to 2 or more weeks. COVID-19 may sometimes cause severe illness such as pneumonia (lung infection) and serious trouble breathing, which can lead to a hospitalization and may possibly cause death.
Older adults and people with long-term health problems, especially of the lungs and heart, are at higher risk of having complications compared to young, healthy children and adults.
Vaccines are the most efficient way of controlling outbreaks and many companies are working to develop vaccines against COVID-19.
The COVID-19 vaccines in this study are either monovalent (containing the spike protein antigen from 1 variant [variant means type of coronavirus]) or bivalent (containing the spike protein antigen from 2 variants). There will be 2 monovalent vaccines and one bivalent vaccine in this study. The monovalent vaccines will contain either the D614 strain (original Wuhan strain) or the B.1.351 strain (Beta variant). The bivalent vaccine includes both the D614 and B.1.351 strains.
The purpose of this study is to determine if these investigational COVID-19 vaccines are safe and can stimulate and broaden the immune response against the different COVID-19 variants that cause COVID-19 when given as a single booster injection in participants who have previously been vaccinated with a full course of an authorized
Am I eligible to participate?
This study is planned to include participants who are 18 years of age and older and have previously been vaccinated against COVID-19. A broad range of people may be included, from those who are healthy to those with health problems that put them at risk for complications due to COVID-19. It is also designed to include older adults and from ethnic and racial minorities.
What does this study involve?
You may or may not benefit from participating in this study. However, your participation will contribute to helping us learn more in the search for another safe and effective COVID-19 vaccine.
If you wish to end your participation in the study, please tell us. If you leave the study for any reason, we may recommend that you come back for certain tests or examinations to check on your health.
Complete this brief questionnaire (approximately 5-10 minutes) to determine if you are eligible to participate in this clinical study.
MAT-GB-2103998(v2.0) Date of preparation: October 2021